CL2015002835A1 - Nuevos derivados de piridina - Google Patents

Nuevos derivados de piridina

Info

Publication number
CL2015002835A1
CL2015002835A1 CL2015002835A CL2015002835A CL2015002835A1 CL 2015002835 A1 CL2015002835 A1 CL 2015002835A1 CL 2015002835 A CL2015002835 A CL 2015002835A CL 2015002835 A CL2015002835 A CL 2015002835A CL 2015002835 A1 CL2015002835 A1 CL 2015002835A1
Authority
CL
Chile
Prior art keywords
pyridine derivatives
new pyridine
new
piridina
aterosclerosis
Prior art date
Application number
CL2015002835A
Other languages
English (en)
Inventor
Tanja Schulz-Gasch
Uwe Grether
Atsushi Kimbara
Matthias Nettekoven
Stephan Roever
Mark Rogers-Evans
Didier Rombach
Olivier Gavelle
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2015002835A1 publication Critical patent/CL2015002835A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

COMPUESTOS DERIVADOS DE PIRIDINA; PROCEDIMIENTO DE OBTENCIÓN; COMPOSICION FARMACEUTICA; Y USO EN EL TRATAMIENTO O PROFILAXIS DEL DOLOR, ATEROSCLEROSIS, DEGENERACION MACULAR PROPIA DE LA VEJEZ, ENTRE OTRAS ENFERMEDADES.
CL2015002835A 2013-03-26 2015-09-23 Nuevos derivados de piridina CL2015002835A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13161176 2013-03-26

Publications (1)

Publication Number Publication Date
CL2015002835A1 true CL2015002835A1 (es) 2016-05-20

Family

ID=47913322

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002835A CL2015002835A1 (es) 2013-03-26 2015-09-23 Nuevos derivados de piridina

Country Status (34)

Country Link
US (2) US10308659B2 (es)
EP (1) EP2978755B1 (es)
JP (1) JP6500010B2 (es)
KR (1) KR20150135458A (es)
CN (1) CN105121436B (es)
AR (1) AR095721A1 (es)
AU (1) AU2014243190B2 (es)
BR (1) BR112015024272A2 (es)
CA (1) CA2899168A1 (es)
CL (1) CL2015002835A1 (es)
CR (1) CR20150440A (es)
DK (1) DK2978755T3 (es)
EA (1) EA027569B1 (es)
ES (1) ES2661737T3 (es)
HK (1) HK1211938A1 (es)
HR (1) HRP20180371T1 (es)
HU (1) HUE036934T2 (es)
IL (1) IL240496B (es)
LT (1) LT2978755T (es)
MA (1) MA38404B1 (es)
MX (1) MX365921B (es)
MY (1) MY174000A (es)
NO (1) NO2978755T3 (es)
PE (1) PE20151559A1 (es)
PH (1) PH12015501933B1 (es)
PL (1) PL2978755T3 (es)
PT (1) PT2978755T (es)
RS (1) RS56927B1 (es)
SG (1) SG11201507994QA (es)
SI (1) SI2978755T1 (es)
TW (1) TWI628174B (es)
UA (1) UA116239C2 (es)
WO (1) WO2014154612A1 (es)
ZA (1) ZA201505251B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2015190316A1 (ja) * 2014-06-09 2017-04-20 住友化学株式会社 ピリジン化合物の製造方法
CN116102449A (zh) * 2015-12-09 2023-05-12 豪夫迈·罗氏有限公司 作为***素受体2激动剂的苯基衍生物
CN109640657B (zh) * 2016-07-07 2020-10-30 美国陶氏益农公司 制备4-烷氧基-3-(酰基或脂族饱和烃基)氧基吡啶甲酰胺的方法
TWI829634B (zh) * 2017-04-06 2024-01-21 美商富曼西公司 殺真菌之噁二唑
AR112199A1 (es) * 2017-06-20 2019-10-02 Hoffmann La Roche Derivados de piridina como agonistas inversos del receptor cannabinoide 2
WO2019003956A1 (ja) * 2017-06-27 2019-01-03 住友化学株式会社 オキサジアゾール化合物及びその用途
CN108774220B (zh) * 2018-05-27 2019-04-23 西安培华学院 用于治疗心肌缺血的化合物及其应用
JP7454512B2 (ja) 2018-06-27 2024-03-22 エフ． ホフマン－ラ ロシュ アーゲー 優先的カンナビノイド２アゴニストとしてのピリジン及びピラジン誘導体
CN114195759B (zh) * 2021-08-26 2023-10-20 上海零诺生物科技有限公司 一种2-甲基-5-（1-甲基吡咯烷-2-基）吡啶制备方法
WO2023069721A2 (en) * 2021-10-22 2023-04-27 Carmot Therapeutics, Inc. Oxazole, oxadiazole, and indole derivatives for the inhibition of usp28
CN115073366A (zh) * 2022-06-08 2022-09-20 都创(重庆)医药科技有限公司 一种基于微通道技术快速制备3-氯吡啶-2-甲酸的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005531520A (ja) * 2002-03-28 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド 置換２，３−ジフェニルピリジン類
EA018724B1 (ru) * 2006-08-07 2013-10-30 Айронвуд Фармасьютикалз, Инк. Соединения индола
EP2211619A1 (en) * 2007-10-18 2010-08-04 Merck Sharp & Dohme Corp. Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
UA111640C2 (uk) 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
CN104395290A (zh) 2012-07-04 2015-03-04 霍夫曼-拉罗奇有限公司 作为***素受体2激动剂的新金刚烷基衍生物
CN104837831B (zh) 2012-12-07 2017-10-31 霍夫曼-拉罗奇有限公司 新的吡啶衍生物
MX2015007156A (es) 2012-12-07 2015-10-14 Hoffmann La Roche Piridina-2-amidas utiles como agonistas receptores de canabinoides 2 (cb2).
PE20151060A1 (es) 2012-12-07 2015-07-25 Hoffmann La Roche Nuevos derivados de pirazina como agonistas del receptor cb2
US9303012B2 (en) 2012-12-07 2016-04-05 Hoffman-La Roche Inc. Pyridine-2-amides useful as CB2 agonists
WO2014135507A1 (en) 2013-03-07 2014-09-12 F. Hoffmann-La Roche Ag Novel pyrazol derivatives
WO2015150438A1 (en) 2014-04-04 2015-10-08 F. Hoffmann-La Roche Ag 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists
CA2943013A1 (en) 2014-04-04 2015-10-08 F. Hoffmann-La Roche Ag Pyridine-2-amides useful as cb2 agonists

Also Published As

Publication number Publication date
PL2978755T3 (pl) 2018-05-30
SG11201507994QA (en) 2015-10-29
LT2978755T (lt) 2018-03-12
CN105121436A (zh) 2015-12-02
MX365921B (es) 2019-06-20
RS56927B1 (sr) 2018-05-31
BR112015024272A2 (pt) 2017-07-18
IL240496A0 (en) 2015-09-24
EP2978755A1 (en) 2016-02-03
MX2015013629A (es) 2016-02-18
AU2014243190B2 (en) 2018-07-19
ES2661737T3 (es) 2018-04-03
CR20150440A (es) 2015-10-08
TWI628174B (zh) 2018-07-01
ZA201505251B (en) 2016-07-27
EA201591567A1 (ru) 2016-01-29
EP2978755B1 (en) 2018-01-03
EA027569B1 (ru) 2017-08-31
SI2978755T1 (en) 2018-03-30
AU2014243190A1 (en) 2015-07-30
HUE036934T2 (hu) 2018-08-28
TW201518287A (zh) 2015-05-16
MY174000A (en) 2020-03-03
PH12015501933A1 (en) 2016-01-11
DK2978755T3 (en) 2018-03-05
MA38404A1 (fr) 2017-01-31
HRP20180371T1 (hr) 2018-04-06
US20190248803A1 (en) 2019-08-15
US20160016968A1 (en) 2016-01-21
WO2014154612A1 (en) 2014-10-02
PT2978755T (pt) 2018-02-26
HK1211938A1 (en) 2016-06-03
KR20150135458A (ko) 2015-12-02
CA2899168A1 (en) 2014-10-02
JP2016516737A (ja) 2016-06-09
IL240496B (en) 2019-03-31
UA116239C2 (uk) 2018-02-26
AR095721A1 (es) 2015-11-04
PH12015501933B1 (en) 2016-01-11
JP6500010B2 (ja) 2019-04-10
CN105121436B (zh) 2018-07-27
US10308659B2 (en) 2019-06-04
PE20151559A1 (es) 2015-11-05
NO2978755T3 (es) 2018-06-02
MA38404B1 (fr) 2017-09-29

Similar Documents

Publication Publication Date Title
CL2015002835A1 (es) Nuevos derivados de piridina
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
CL2015002387A1 (es) Nuevos derivados de pirazol.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
CL2015003442A1 (es) Derivados heterociclicos
MY187540A (en) Compounds active towards bromodomains
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2015002897A1 (es) Inhibidores de bace1
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CL2015000891A1 (es) Compuestos derivados de fenil-etinilo, moduladores de la actividad del receptor mglur5; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la ansiedad, dolor, depresion,entre otras.
ECSP18060864A (es) Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
ECSP18060820A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
CL2016000884A1 (es) Derivados de piperazina y su uso como medicamento.